The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Vivimed strategy is to increase its share of Branded products in CIS Markets.
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
The company will review FDA's response and decide on appropriate next steps soon.
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
Fluphenazine Hydrochloride Tablets, USP are available in 1 mg, 2.5 mg, 5 mg, and 10 mg tablets in 100 bottle count sizes.
Subscribe To Our Newsletter & Stay Updated
